Stem cell transplant for high-risk multiple myeloma
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests a stem cell transplant using a donor's cells (allogeneic transplant) to treat high-risk multiple myeloma that has returned or not responded to treatment. It aims to replace the diseased bone marrow with healthy donor cells that can fight the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Aged 18 to 65 years
- Diagnosed with high-risk multiple myeloma that has relapsed or not responded to standard treatments
- Have a suitable related or unrelated donor who is a close tissue match
- Adequate organ and blood count function
- Willing to follow the study schedule and use contraception if applicable
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study combines a stem cell transplant with a special immune therapy (CAR-T) to treat multiple myeloma that is very aggressive and has not responded well to initial treatments. The goal is to see if this combination can better control the cancer.
This Phase 1 study tests a personalized (tailored) autologous stem cell transplant for people with multiple myeloma or related plasma cell diseases. The goal is to see how safe it is and how well it works, using your own stem cells.
This trial looks at people with newly diagnosed multiple myeloma who have no detectable cancer cells after initial treatment. It aims to see if these patients can do well without a stem cell transplant or with a delayed one, reducing unnecessary side effects.
This trial tests a stem cell transplant followed by two targeted therapies — a BCMA CAR-T and a GPRC5D/CD3 bispecific antibody — to treat newly diagnosed multiple myeloma that has ultra-high-risk features. The goal is to see if this combination can better control the disease.
This trial tests a specific chemotherapy combination (thiotepa and melphalan) given before a stem cell transplant to treat multiple myeloma. The study compares this approach to help doctors understand if it improves outcomes for patients whose myeloma hasn't fully responded to initial treatment.
This trial tests combining CAR-T cell therapy with a donor stem cell transplant for multiple myeloma that has come back or not responded to treatment. It aims to see if this approach can help when other treatments have failed.
Hear when a new Recurrent Multiple Myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.